kresmion.
Pull a receipt

Moleculin Biotech, Inc. (MBRX)

Sector
Healthcare
Industry
Biotechnology
Last price
$8.70
As of

Kresmion compiles this page from MBRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Moleculin Biotech, Inc. (MBRX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.

As of . Source: SEC EDGAR filings for MBRX. Method and limitations.

COMPANY DOSSIER

See the full MBRX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for MBRX on one page. Preview it with sample data, then open it live with a free account.

Preview the MBRX dossier

Active events for MBRX

  • mediumEarnings above estimates

    Q2-2026: Beat consensus by 11.6%, EPS $-1.40 vs $-1.5844 estimate

    All 2026-09-01 events →
  • mediumEarnings below estimates

    Q2-2025: Missed consensus by 32.2% - EPS $-12.25 vs $-9.2649 estimate

    All 2026-06-02 events →
  • mediumEarnings below estimates

    Q3-2025: Missed consensus by 241.9% - EPS $-17 vs $-4.9725 estimate

    All 2026-06-02 events →
  • mediumEarnings above estimates

    Q4-2025: Beat consensus by 309.1% - EPS $13.04 vs $-6.2356 estimate

    All 2026-06-02 events →
  • mediumEarnings below estimates

    Q1-2026: Missed consensus by 108.7% - EPS $-3.54 vs $-1.6966 estimate

    All 2026-06-02 events →

FREE, NO ACCOUNT

Every event on MBRX, as it fires

New filings, 13F moves and cross asset events on MBRX land in the record first.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, MBRX

Going concern statement

MBRX's 10-Q filed Aug 13, 2026 states:

These factors raise substantial doubt regarding the Company's ability to continue as a going concern.

Read the 10-Q on SEC EDGAR Every company with a going concern statement

More data on MBRX

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in MBRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on MBRX in the last 180 days.

Upstream: SEC EDGAR filings for MBRX

Kresmion, "Moleculin Biotech, Inc. (MBRX) institutional holdings and SEC filings", data as of 2026-11-04, https://kresmion.com/research/MBRX. Upstream data: SEC EDGAR filings for MBRX.

Link to this data (HTML):

<a href="https://kresmion.com/research/MBRX">Moleculin Biotech, Inc. (MBRX) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow MBRX on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to MBRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the MBRX dossier
Share

The MBRX intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.